Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial - Concepedia

Concepedia

Publication | Open Access

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

DOI Full Paper Access

31

Citations

34

References

2024

Year

Rebecca Shatsky, Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian, Butch Tsiatis, Anne M. Wallace, A. Jo Chien, Erica Stringer-Reasor,

Nature Medicine

Breast OncologySequential Multiple AssignmentMedicineImmunologyPathologyImmune Checkpoint InhibitorBreast CancerI-spy2.2 Phase 2Anti-cancer AgentCancer TreatmentOncologyRadiation OncologyEarly-stage Breast Cancer

References

	Year	Citations

Page 1

Page 1